Freedom Investment Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Freedom Investment Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-6,198	Closed	-$200K	–	831
2022 Q1	$200K	Buy	+6,198	New	+$190K	0.02%	729
2021 Q3	–	Sell	-7,230	Closed	-$223K	–	899
2021 Q2	$223K	Sell	7,230 -497	-6%	-$15.2K	0.02%	792
2021 Q1	$202K	Buy	+7,727	New	+$216K	0.02%	789
2019 Q2	–	Sell	-10,735	Closed	-$376K	–	731
2019 Q1	$376K	Buy	+10,735	New	+$399K	0.03%	453
2018 Q4	–	Sell	-6,266	Closed	-$275K	–	886
2018 Q3	$275K	Sell	6,266 -8,597	-58%	-$425K	0.02%	737
2018 Q2	$890K	Buy	14,863 +9,412	+173%	+$488K	0.05%	367
2018 Q1	$250K	Buy	+5,451	New	+$227K	0.01%	942
2017 Q3	–	Sell	-8,607	Closed	-$371K	–	1147
2017 Q2	$371K	Buy	+8,607	New	+$306K	0.02%	689

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Freedom Investment Management's SUPN Position: Q2 2022 in Review

Freedom Investment Management sold out of Supernus Pharmaceuticals (SUPN) in Q2 2022, closing a stake of 6,198 shares — an estimated $200K sold.

Freedom Investment Management first reported a position in SUPN in Q2 2017 and held it in 8 quarters. The position peaked at $890K in Q2 2018. 225 funds tracked by Wall St. Rank hold SUPN as of Q2 2022.

Freedom Investment Management reported no remaining Supernus Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Freedom Investment Management sold 6,198 Supernus Pharmaceuticals shares in Q2 2022, an estimated $200K.
Freedom Investment Management first reported a position in Supernus Pharmaceuticals in Q2 2017 and held it in 8 quarters.
Freedom Investment Management's Supernus Pharmaceuticals position peaked at $890K in Q2 2018.
225 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2022.

Based on Freedom Investment Management's 13F filing for Q2 2022, filed 8 Aug 2022.